Here is the most important thing to understand about GLP-1 insurance coverage in 2026: the same molecule — semaglutide — may be covered or denied depending entirely on what brand name is on your prescription and what diagnosis code your doctor submitted. Ozempic (semaglutide for type 2 diabetes) is covered by approximately 85% of commercial plans. Wegovy (semaglutide for obesity) is covered by only about 45%. Same drug. Different coverage. The reason is regulatory and historical, and it has nothing to do with clinical evidence.
As of mid-2026, 27 million people still lack coverage for Wegovy, and 88% of those who have coverage face prior authorization requirements or other restrictions. This guide explains what coverage actually exists and exactly what to do when you are denied.
Medicare launched the GLP-1 Bridge program in July 2026 — offering Wegovy, Zepbound KwikPens, and the new oral GLP-1 Foundayo at a $50 monthly copay for eligible enrollees. Blue Cross Massachusetts dropped weight-loss GLP-1 coverage in January 2026. California’s Medi-Cal is dropping weight-loss GLP-1 coverage. Coverage is moving in opposite directions across different markets simultaneously.
Coverage by Plan Type
| Plan Type | Coverage for Diabetes (Ozempic/Mounjaro) | Coverage for Obesity (Wegovy/Zepbound) |
|---|---|---|
| Commercial/Employer (large employer) | ~85% covered; usually requires PA | ~45% covered; heavily restricted; PA almost always required |
| ACA Marketplace | Usually covered if diabetes diagnosis | Varies by state and plan; often excluded |
| Medicare Part D | Covered for diabetes; some CV risk indications | Bridge program: $50/mo copay for Wegovy, Zepbound, Foundayo (July 2026+) |
| Medicaid | Varies by state; generally covered for diabetes | 13 states cover as of Jan 2026; California dropping it |
| Self-insured employer plan | Depends on employer plan design | Depends on employer; exclusions common |
Why Ozempic Is Covered but Wegovy Often Is Not
This is the question most people ask when they learn their diabetes neighbour on Ozempic pays $30 a month while they pay $800 out-of-pocket for Wegovy. Both medications contain semaglutide at the same doses. The difference traces to FDA approval dates and historical insurance policy design.
In the 1990s and early 2000s, several weight-loss drugs — most notably Fen-Phen — caused serious cardiac harm and were pulled from the market. Employers and insurers responded by adding blanket “weight loss drug” exclusions to their benefit plans. Those exclusions were written generically enough to apply to any medication with an obesity indication, regardless of its actual safety profile. When Wegovy received FDA approval in 2021 with an obesity indication, it walked directly into those decades-old exclusions.
Ozempic, with its diabetes indication, did not. This is why coverage follows the indication, not the molecule.
How Prior Authorization Works for GLP-1s
Even when your plan covers GLP-1 medications, coverage almost always requires prior authorisation. Your pharmacy submits your prescription to the insurer, who reviews whether you meet their criteria. Most plans require:
- A documented diagnosis of type 2 diabetes (for Ozempic/Mounjaro) or obesity/cardiovascular risk (for Wegovy/Zepbound)
- A minimum BMI — typically 30, or 27 with at least one weight-related comorbidity (high blood pressure, sleep apnea, prediabetes, high cholesterol)
- Documentation that you have attempted prior treatments — lifestyle modifications, metformin for diabetes, other weight-loss interventions
- Your prescribing physician’s notes confirming all of the above
The most common reason a GLP-1 prior auth is denied: one of these documentation elements is missing from the submission. Often the fix is simply having your doctor resubmit with the complete clinical picture.
If You Are Denied: What to Do Next
Get the denial reason in writing. Under 2026 CMS rules for most plans, your insurer must provide a specific clinical reason for any prior auth denial. Call and request this if it is not in your denial letter. The specific language tells you exactly what your appeal needs to argue.
Distinguish between “criteria not met” and “excluded from coverage.” These are different situations. “Criteria not met” means you failed to meet the plan’s specific eligibility requirements — and you can appeal with additional documentation. “Excluded from coverage” means the benefit category is not part of your plan at all. Excluded benefits generally cannot be appealed, though a plan exclusion can sometimes be challenged if your state has laws requiring coverage of the service.
Appeal with your comorbidities front and centre. Many denials for obesity-indication GLP-1s are reversed when the doctor’s appeal letter documents comorbidities that the original submission did not emphasise. If you have high blood pressure, sleep apnea, prediabetes, a family history of cardiovascular disease, or any other weight-related health condition, your physician’s appeal letter should make these the centrepiece of the medical necessity argument.
If you have cardiovascular disease or risk factors, cite the SELECT trial. The 2023 SELECT cardiovascular outcomes trial found that Wegovy reduced major adverse cardiovascular events by 20% in people with established cardiovascular disease. This clinical data has led to expanded coverage indications and is a strong basis for medical necessity arguments in patients with cardiac risk profiles.
If Coverage Is Not Available: What Things Cost Without Insurance
The list price for GLP-1 medications is high, but self-pay options have expanded considerably in 2026:
- NovoCare Pharmacy (Novo Nordisk direct): Wegovy or Ozempic pills from $149/month; pens from $199/month
- LillyDirect (Eli Lilly direct): Zepbound KwikPens from $299/month (2.5 mg) to $449/month (higher doses)
- GoodRx for Weight Loss: Discounted access to brand-name GLP-1 medications through the GoodRx platform
- Manufacturer copay cards: Novo Nordisk and Eli Lilly offer savings programs for commercially insured patients who pay out of pocket; these do not apply to Medicare or Medicaid
